IAMGOLD Corp. (NYSE:IAG)

IAMGOLD Corp is an international gold exploration and mining company based in Canada. It holds a 38% stake in the Sadiola Gold Mine and a 40% stake in the Yatela Gold Mine. Both are located in Mali, West Africa. Measured and indicated resources at Sadiola and Yatela are 5.5 million ounces of gold (including reserves of 5.2 million ounces). Inferred resources are 5.9 million ounces. IAMGOLD is actively exploring highly prospective ground in Africa and South America.

IAMGOLD Corp. (NYSE:IAG)’s Financial Overview

IAMGOLD Corp. (NYSE:IAG) surged 0.27% yesterday to close its trading session at $3.76. The company has 1 year Price Target of $5.41. IAMGOLD Corp. has 52-Week high of $5.87 and 52-Week Low of $1.15. The stock touched its 52-Week High on Aug 4, 2016 and 52-Week Low on Jan 20, 2016. The stock traded with the volume of 6.79 Million shares yesterday. The firm shows the market capitalization of $1.69 Billion.

IAMGOLD Corp. (NYSE:IAG) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $0.05/share against the analyst consensus estimate of $0.01/share. The difference between the actual and expected EPS is $0.04 a share with a surprise factor of 400%.

The firm is trading with SMA20 of -3.65 Percent, SMA50 of -2.85 Percent and SMA200 of 2.51 percent. IAMGOLD Corp. has P/S value of 1.74 while its P/B value stands at 0.72. Similarly, the company has Return on Assets of -18.6 percent, Return on Equity of -30.5 percent and Return on Investment of -29.7 Percent. The company shows Gross Margin and Operating Margin of 3.9 percent and -67.6 percent respectively.

Many brokerage firms are involved in issuing their ratings on IAMGOLD Corp. (NYSE:IAG). On 8-Nov-16 TD Securities Upgrade IAMGOLD Corp. Stock  to Buy. Another firm also rated the stock on 18-Aug-16 where Credit Suisse Initiated the stock to Neutral.

The Stock currently has Analyst’ mean Recommendation of 2.6 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 16 analysts offering 12-month price forecasts for IAMGOLD Corp have a median target of 5.53, with a high estimate of 7.50 and a low estimate of 3.13. The median estimate represents a +47.04% increase from the last price of 3.76.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Exelixis, Inc. (NASDAQ:EXEL)

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.

Exelixis, Inc. (NASDAQ:EXEL)’s Financial Outlook

The 5 analysts offering 12-month price forecasts for Exelixis Inc have a median target of 17.00, with a high estimate of 21.00 and a low estimate of 5.00. The median estimate represents a +0.06% increase from the last price of 16.99.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Exelixis, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock gained 3.03% and closed its last trading session at $16.99. The company has the market capitalization of $4.87 Billion. The stock has 52-week high of $17.39 and 52-Week low of $3.55. The firm touched its 52-Week high on Nov 22, 2016 and 52-Week low on Mar 17, 2016. The company has volume of 6.76 Million shares. The company has a total of 286.46 Million shares outstanding.

Exelixis, Inc. (NASDAQ:EXEL) in the last quarter reported its actual EPS of $-0.04/share where the analyst estimated EPS was $-0.12/share. The difference between the actual and Estimated EPS is $0.08. This shows a surprise factor of 66.7 percent.

The company has YTD performance of 201.24 percent. Beta for Exelixis, Inc. stands at 1.8 while its ATR (average true range) is 0.87. The company has Weekly Volatility of 6.21%% and Monthly Volatility of 6.59%%.

Exelixis, Inc. has distance from 20-day Simple Moving Average (SMA20) of 15.76%, Distance from 50-Day Simple Moving Average of 26.16 percent and Distance from 200-Day Simple Moving Average of 97.65%.

The Company currently has ROA (Return on Assets) of -36 percent, Return on Equity (ROE) of 160.9 Percent and Return on Investment (ROI) of -43.8% with Gross margin of 95.4 percent and Operating & Profit margin of 0% and 0% respectively.